Cancer biomarkers in HIV patients

Current Opinion in HIV and AIDS

Volumn 5, Issue 6, 2010, Pages 531-537

  Ambinder, Richard F ^a   Bhatia, Kishor ^b   Martinez Maza, Otoniel ^c   Mitsuyasu, Ronald ^c,d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UCLA MEDICAL CENTER   (United States)

Author keywords

Cervical cancer; HIV; Hodgkin's; Kaposi's sarcoma; lymphoma

Indexed keywords

BIOLOGICAL MARKER; CD30 ANTIGEN; CYTIDINE DEAMINASE; CYTOKINE; IMMUNOGLOBULIN LIGHT CHAIN; INTERLEUKIN 10;

BURKITT LYMPHOMA; CYTOKINE PRODUCTION; EPSTEIN BARR VIRUS; GENETIC POLYMORPHISM; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LYMPHOCYTE COUNT; LYMPHOMA; NEOPLASM; NONHODGKIN LYMPHOMA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; VIRUS LOAD; WART VIRUS;

CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VIRAL LOAD;

EID: 78049282376     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833f327e     Document Type: Review

References (45)

1. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillo-mavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009; 101:1120-1130.
2. Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009; 52:611-622.
3. Kirk GD, Merlo C, O'Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007; 45:103-110.
4. Levine AM, Seaberg EC, Hessol NA, et al. HIV as a risk factor for lung cancer in women: data from the Women's Interagency HIV Study. J Clin Oncol 2010; 28:1514-1519
5. Matthews GV, Bower M, Mandalia S, et al. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000; 96:2730-2734.
6. Stebbing J,Gazzard B, Mandalia S, et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 2004; 22:2177-2183.
7. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99:962-972.
8. Bower M, Fisher M, Hill T, et al. CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica 2009; 94:875-880.
9. Zoufaly A, Stellbrink HJ, Heiden MA, et al. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis 2009; 200:79-87.
10. + T cell counts. PLoS Med 2007; 4:e96.
11. Engels EA, Pfeiffer RM, Landgren O, Moore RD. Immunologic and virologic predictors of AIDS-related nonhodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2010; 54:78-84.
12. Epeldegui M, Thapa DR, De La Cruz J, et al. CD40 ligand (CD154) incorporated into HIV virions induces activation-induced cytidine deaminase (AID) expression in human B lymphocytes. PLoS One 2010; 5:e11448.
13. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodefi ciency in persons with HIV/AIDS. Blood 2006; 108:3786-3791.
14. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27:884-890.
15. Clifford GM, Rickenbach M, Lise M, et al. Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood 2009; 113:5737-5742.
16. Dolcetti R, De Paoli P, Serraino D. Degree of immune suppression and risk of HIV-related Hodgkin lymphoma: time points matter. Blood 2009; 114:2354; author reply 2354-2355.
17. Clifford G, Franceschi S, Rickenbach M. Response: lymphocyte counts prior to Hodgkin lymphoma development. Blood 2009; 114:2354-2355.
18. Lodi S, Guiguet M,CostagliolaD, et al. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst 2010; 102:784-792.
19. Guiguet M, BoueF, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10:1152-1159.
20. Skibola CF, Bracci PM, Nieters A, et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol 2010; 171:267-276.
21. Fernberg P, Chang ET, Duvefelt K, et al. Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma. Cancer Causes Control 2010; 21:759-769.
22. Wang SS, Purdue MP, Cerhan JR, et al. Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk. PLoS One 2009; 4:e5360.
23. Dean M, Jacobson LP, McFarlane G, et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res 1999; 59:3561-3564.
24. Rabkin CS, Yang Q, Goedert JJ, et al. Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1-infected individuals. Blood 1999; 93:1838-1842.
25. Breen EC, Boscardin WJ, Detels R, et al. Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype. Clin Immunol 2003; 109:119-129.
26. Bracci PM, Skibola CF, Conde L, et al. Chemokine polymorphisms and lymphoma: a pooled analysis. Leuk Lymphoma 2010; 51:497-506.
27. Wong H-L, Breen EC, Pfeiffer RM, et al. Cytokine signaling pathway poly- morphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study. AIDS 2010; 24:1025-1033.
28. Coelho A, Matos A, Catarino R, et al. Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma. Gynecol Oncol 2005; 96:760-764.
29. Chatterjee K, Dandara C, Hoffman M, Williamson A-L. CCR2-V64I polymorphism is associated with increased risk of cervical cancer but not with human papillomavirus (HPV) infection or precancerous lesions in African women. BMC Cancer 2010; 10:278.
30. Aissani B, Ogwaro KM, Shrestha S, et al. The major histocompatibility complex conserved extended haplotype 8.1 in AIDS-related non-Hodgkin lymphoma. J Acquir Immune Defic Syndr 2009; 52:170-179.
31. Grulich AE, Wan X, Law MG, et al. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2000; 14:133-140.
32. Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol 2010; 28:773-779.
33. Breen EC, van der Meijden M, Cumberland W, et al. The development of AIDS-associated Burkitt's/small noncleaved cell lymphoma is preceded by elevated serum levels of interleukin 6. Clin Immunol 1999; 92:293-299.
34. Schroeder JR, Saah AJ, Hoover DR, et al. Serum soluble CD23 level correlates with subsequent development of AIDS-related non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 1999; 8:979-984.
35. Breen EC, Fatahi S, Epeldegui M, et al. Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol 2006; 27:187-194.
36. Purdue MP, Lan Q, Martinez-Maza O, et al. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood 2009; 114:2730-2732.
37. Cinque P, Cingolani A, Bossolasco S, Antinori A. Positive predictive value of Epstein-Barr virus DNA detection in HIV-related primary central nervous system lymphoma. Clin Infect Dis 2004; 39:1396-1397; author reply 1397-1398.
38. Corcoran C, Rebe K, van der Plas H, et al. The predictive value of cerebrospinal fluid Epstein-Barr viral load as a marker of primary central nervous system lymphoma in HIV-infected persons. J Clin Virol 2008; 42:433-436.
39. Fellner M, Durand K, Correa R, et al. Circulating Epstein-Barr virus (EBV) in HIV-infected patients and its relation with primary brain lymphoma. Int J Infect Dis 2007; 11:172-178.
40. Bonnet F, Jouvencel A, Parrens M, et al. A longitudinal and prospective study of Epstein-Barr virus load in AIDS-related non-Hodgkin lymphoma. J Clin Virol 2006; 36:258-263.
41. Amiel C, Legoff J, Lescure FX, et al. Epstein-Barr virus load in whole blood correlates with HIV surrogate markers and lymphoma: a French national cross-sectional study. J Acquir Immune Defic Syndr 2009; 50:427-429.
42. Lin L, Lee JY, Kaplan LD, et al. Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood. Clin Oncol 2009; 27:2496-2502.
43. Borok M, Fiorillo S, Gudza I, et al. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe. Clin Infect Dis 2010; 51:342-349.
44. Canadas M-P, Darwich L, Sirera G, et al., Group H-HCRS:. Human papillomavirus 16 integration and risk factors associated in anal samples of HIV-1 infected men. Sex Transm Dis 2010; 37:311-315.
45. Blaes AH, Cao Q, Wagner JE, et al. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin con taining nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant 2010; 16:287-291.